{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biological+Markers&page=90",
    "query": {
      "condition": "Biological Markers",
      "page": 90
    },
    "page_size": 10
  },
  "pagination": {
    "page": 90,
    "page_size": 10,
    "total_count": 3313,
    "total_pages": 332,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biological+Markers&page=91&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biological+Markers&page=89&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T22:48:51.782Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04134923",
      "title": "Imaging Biomarkers in Preclinical and Symptomatic AD",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "[11C] Pittsburgh Compound-B (PIB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tammie L. S. Benzinger, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2021-06-08",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134923"
    },
    {
      "nct_id": "NCT01034579",
      "title": "The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2010-02",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034579"
    },
    {
      "nct_id": "NCT04074486",
      "title": "Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Injuries",
        "Concussion, Mild",
        "Concussion, Brain",
        "Near Point Convergence",
        "Concussion, Intermediate"
      ],
      "interventions": [
        {
          "name": "BrainScope Ahead 300iP-O",
          "type": "DEVICE"
        },
        {
          "name": "SCAT5",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Near Point Convergence",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "BrainScope Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "13 Years to 50 Years"
      },
      "enrollment_count": 1318,
      "start_date": "2019-10-02",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 6,
      "location_summary": "Fayetteville, Arkansas • Storrs, Connecticut • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Storrs",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04074486"
    },
    {
      "nct_id": "NCT01756690",
      "title": "Predicting Lung Injury From Transfusion in Patients With Liver Disease",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transfusion-related Acute Lung Injury",
        "Chronic Liver Disease",
        "Gastrointestinal Bleeding"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-10",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Denver, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01756690"
    },
    {
      "nct_id": "NCT00788359",
      "title": "Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2007-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00788359"
    },
    {
      "nct_id": "NCT03201991",
      "title": "ALS Study Determining Various Biomarkers and Strength Comparison After Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Resistance Exercise Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-05-01",
      "completion_date": "2018-04-18",
      "has_results": false,
      "last_update_posted_date": "2019-12-19",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03201991"
    },
    {
      "nct_id": "NCT02091882",
      "title": "Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Device Latency"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Combination product of Aripiprazole + IEM + Sensor + MIND1 Application",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03-21",
      "completion_date": "2014-04-18",
      "has_results": true,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 1,
      "location_summary": "Walnut Creek, California",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091882"
    },
    {
      "nct_id": "NCT01117623",
      "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "NSCLC expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2007-02",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117623"
    },
    {
      "nct_id": "NCT01576003",
      "title": "Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bloodstream Infections",
        "Short Bowel Syndrome",
        "Development",
        "Nutrition",
        "Biological Markers"
      ],
      "interventions": [
        {
          "name": "Glutamine",
          "type": "DRUG"
        },
        {
          "name": "L-alanine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Months"
      },
      "enrollment_count": 10,
      "start_date": "2012-04",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576003"
    },
    {
      "nct_id": "NCT01847001",
      "title": "Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Malignant Neoplasm",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "DOT imaging",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Premedication",
          "type": "DRUG"
        },
        {
          "name": "Anti-nausea therapy",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2012-10",
      "completion_date": "2019-10-16",
      "has_results": true,
      "last_update_posted_date": "2021-09-10",
      "last_synced_at": "2026-11-20T22:48:51.782Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847001"
    }
  ]
}